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Background: Aspirin has been associated with a reduced risk of colorectal cancer, and possibly of a few other digestive
tract cancers. The quantification of risk reduction and the optimal dose and duration of aspirin use for the prevention of
colorectal and other digestive tract cancers remains unclear.
Methods: To provide an up-to-date quantification of this association, we conducted a systematic review and meta-
analysis of all observational studies on aspirin and cancers of the digestive tract sites published through March
2019. We estimated the pooled relative risk (RR) of cancer for regular aspirin use versus non-use using random-
effects models, and, whenever data were available, we investigated the dose- and duration-risk relations.
Results: Regular aspirin use is associated with a reduced risk of colorectal cancer [RR ¼ 0.73, 95% confidence interval
(CI) ¼ 0.69e0.78, 45 studies], squamous-cell esophageal cancer (RR ¼ 0.67, 95% CI ¼ 0.57e0.79, 13 studies),
adenocarcinoma of the esophagus and gastric cardia (RR ¼ 0.61, 95% CI ¼ 0.49e0.77, 10 studies), stomach cancer
(RR ¼ 0.64, 95% CI ¼ 0.51e0.82, 14 studies), hepato-biliary tract cancer (RR ¼ 0.62, 95% CI ¼ 0.44e0.86, five
studies), and pancreatic cancer (RR ¼ 0.78, 95% CI ¼ 0.68e0.89, 15 studies), but not of head and neck cancer
(RR ¼ 0.94, 95% CI ¼ 0.76e1.16, 10 studies). The associations are somewhat stronger in case-control than in
cohort and nested case-control studies and are characterized by some between-study heterogeneity. Risk estimates
are consistent across sex, geographical areas, and other selected covariates. For colorectal cancer, an aspirin dose
between 75 and 100 mg/day conveys a risk reduction of 10%, and a dose of 325 mg/day of 35%. For all neoplasms,
except head and neck cancer, inverse duration-risk relations with aspirin use are found.
Conclusion: The present comprehensive meta-analysis supports and further quantifies the inverse association between
regular aspirin use and the risk of colorectal and other digestive tract cancers, including some rare ones. The favorable
effect of aspirin increases with longer duration of use, and, for colorectal cancer, with increasing dose.
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Aspirin has long been associated with a reduced risk of
colorectal and possibly a few other cancers.1 The evidence
comes mainly from a large number of observational
studies,2 but has been corroborated by the results of pooled
analyses of randomized clinical trials (RCTs) for the primary
or secondary prevention of vascular events.3e5
In a meta-analysis of observational studies published up
to September 2011, significant risk reductions were re-
ported for colorectal [relative risk (RR) 0.73], and esopha-
geal and stomach cancer (RRs between 0.61 and 0.67) for*Correspondence to: Dr Cristina Bosetti, Department of Oncology, Istituto di
Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan,
Italy. Tel: þ39 0239014526; Fax: þ39 0233200231
E-mail: cristina.bosetti@marionegri.it (C. Bosetti).
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558 https://doi.org/10.1016/j.annonc.2020.02.012regular aspirin use versus non-use.2 Consistent risk re-
ductions were reported in a few other meta-analyses on the
same topic conducted over the last few years.6e8
The role of aspirin in other cancers of the digestive tract
is, however, still controversial. Moreover, the optimal dose
and duration of aspirin use for the prevention of colorectal
and other digestive tract cancers remains unclear.
In order to provide the most up-to-date and compre-
hensive estimates for the chemopreventive role of aspirin
on cancers of the digestive tract (i.e. colorectal, head and
neck, esophageal, stomach, hepato-biliary, and pancreas),
we updated the systematic review and meta-analysis of
observational studies published in 2012,2 including infor-
mation from several case-control and cohort studies pub-
lished over the last few years. We also further investigated
the dose- and duration-risk relations of aspirin use and
colorectal cancer, and, whenever sufficient data were
available, other digestive cancers.Volume 31 - Issue 5 - 2020
C. Bosetti et al. Annals of OncologyMATERIALS AND METHODS
Search strategy
The present systematic review and meta-analysis was con-
ducted according to the PRISMA guidelines9,10 and its pro-
tocol was registered on the International Prospective
Register of Systematic Review (PROSPERO; No.
CRD42019132359). Briefly, we carried out an updated
literature search to identify all original study publications
from observational studies on aspirin use and cancer risk
published between 1 January 2011 (i.e. year of publication
of the meta-analysis by Bosetti et al.2) and 18 March 2019,
and indexed in PubMed/Medline, Embase, and the
Cochrane Library. The search strings used in each database
are provided in supplementary Table S1, available at Annals
of Oncology online. Additional articles were identified
through a manual check of the references of selected pa-
pers or other systematic reviews/meta-analyses.Eligibility criteria
In the present meta-analysis, we included studies which
satisfied the following eligibility criteria: (i) they were case-
control (including pooled analyses of case-control studies),
nested case-control, or cohort studies (including pooled
analyses of cohort studies); (ii) they provided data on
humans in the general population; (iii) they provided in-
formation on regular aspirin use (i.e. use at least one or two
tablets per week) or, alternatively, on any use; (iv) they
focused on at least one of 14 major malignant neoplasms
(i.e. head and neck cancer, squamous-cell esophageal can-
cer, adenocarcinoma of the esophagus and gastric cardia,
colorectum, stomach, hepato-biliary, pancreas, lung, breast,
endometrium, ovary, prostate, bladder, and kidney); (v) they
reported RR estimatesdincluding odds ratios, hazard ratios,
or mortality rate ratiosdfor the selected neoplasms, in
relation to aspirin use versus non-use, and the corre-
sponding 95% confidence interval (CI), or provided suffi-
cient information to compute them; and (vi) they were
published as original articles in English.We excluded articles
based on patients with specific diseases, as well as those
evaluating cancer survival and recurrence.We also excluded
studies reporting information on the use of other anti-
inflammatory drugs or combinations of aspirin with other
anti-inflammatory drugs.We did not assign quality scores to
the studies and no study was excluded a priori for weakness
of design or data quality.
Two reviewers (CS and MM) independently screened the
titles and/or abstracts of the identified publication records,
in order to exclude those that did not meet the eligibility
criteria. Subsequently, they retrieved and assessed the full-
text of the selected articles. Any disagreement was solved
by consensus between the two reviewers, or with the help
of a third reviewer (CB).Data extraction
For each eligible study, we abstracted the following relevant
information: first author, publication year, study design,Volume 31 - Issue 5 - 2020country, cancer site and/or subsite, end point, type of
controls, number of cases and controls (or subjects at risk/
person years for cohort studies), and RR estimates for
aspirin use versus non-use, with the corresponding 95% CI.
When available, we also retrieved information on aspirin
formulation (low dose, i.e. 75e100 mg, regular dose, i.e.
325 mg, or high dose, i.e. 500 mg), daily dose (mg), fre-
quency (times per month, week, or day), and duration
(years) of aspirin use.
When the results of the same study were published in
multiple publications, we abstracted data only from the
most recent and informative one. We also checked over-
lapping information between pooled analyses and original
studies and, for some pooled analyses, we only included
information not provided in separate study publications.Statistical analysis
For each neoplasm of interest, we derived pooled RRs for
regular aspirin use versus no use, overall, and by study
design. These estimates were obtained using random-
effects models, to take into account heterogeneity of risk
estimates.10,11 For cohort studies providing estimates both
for incidence and mortality, in the main analysis we pooled
data on incidence, unless the results on mortality were
more recent and included a larger number of cases. We
assessed heterogeneity between studies using the
Cochran’s c2 test and quantified the inconsistencies using
the I2 statistic.12 To identify possible sources of heteroge-
neity between studies, we carried out stratified analyses
considering selected a priori variables, such as study design,
year of publication, geographic area, sex, end point, type of
controls. When required, we computed estimates of the RR
for regular aspirin use by pooling the RRs for various cate-
gories of frequency or duration of use, using the method
described by Hamling et al.13 To evaluate publication bias,
we examined the funnel plots and applied the Egger’s and
Begg’s tests for funnel plot asymmetry.10,12
For cancers with sufficient information, we investigated
linear and nonlinear relations between daily dose and
duration of aspirin use and the log-RR of cancer. When in-
formation on the daily dose of aspirin was not available, we
computed it by combining information on aspirin formula-
tion and frequency of use. We tested the log-linearity using
the Wald test; we then used one-stage random-effects log-
linear models in the case of linearity, or restricted cubic
splines with three knots when linearity was rejected.14e17
All statistical analyses were carried out using the soft-
ware SAS version 9.4 (SAS Institute, Cary, NC) and R version
3.4.1 (R Development Core Team, 2017; in particular, the
‘meta’ and ‘dosresmeta’ packages18).
RESULTS
Supplementary Figure S1, available at Annals of Oncology
online, shows the flowchart for study selection. From 1575
records published between 2011 and 2019 on aspirin and
cancer risk, after excluding duplicate or not eligible records,
we identified 92 articles. Considering 150 additional articleshttps://doi.org/10.1016/j.annonc.2020.02.012 559
Annals of Oncology C. Bosetti et al.published before 2012 (already included in Bosetti et al.2 or
identified from manual searches), we ended up with 242
eligible articles. Of these, 113 focused on colorectal and other
digestive tract cancers and were included in the present
meta-analysis. The main characteristics of the cohort, nested
case-control, and case-control studies included are given in
supplementary Tables S2eS8, available at Annals of Oncology
online. Eligible studies excluded from the meta-analysis,
since their information was already included in more recent
or complete papers, are provided in supplementary
Tables S9eS14, available at Annals of Oncology online.
Colorectal cancer
Sixty-six studies provided information on aspirin and colorectal
risk (supplementary Tables S2 and S9, available at Annals of
Oncology online). Of these, 45 studies (15 cohort, 11 nested
case-control, and 19 case-control studies, of which four were
derived from a pooled analysis19) contributed to the estimate
of regular aspirin use versus non-use, including a total of 156
019 cases (Table 1). A significant reduced riskwas observed for
regular aspirin use (RR ¼ 0.73, 95% CI ¼ 0.69e0.78), with a
stronger inverse relation in case-control (RR¼ 0.62, 95% CI¼
0.56e0.69) than in cohort (RR ¼ 0.77, 95% CI ¼ 0.72e0.82)
and nested case-control studies (RR ¼ 0.86, 95% CI ¼ 0.78eTable 1. Pooled relative risks (RR) and corresponding 95% confidence intervals
Cancer site, study design No. of studies No. of cases
Colorectum
Cohort 15 33 126
Nested case-control 11 105 607
Case-control 19 17 286
Overall 45 156 019
Head and neck
Cohort 1 316
Nested case-control 2 3940
Case-control 7 6143
Overall 10 10 399
Esophagus (squamous-cell)
Cohort 4 2873
Nested case-control 2 2070
Case-control 7 1268
Overall 13 6211
Esophagus/gastric cardia (adenocarcinoma)
Cohort 2 481
Case-control 8 2540
Overall 10 3021
Stomach
Cohort 6 6748
Nested case-control 1 980
Case-control 7 2191
Overall 14 9919
Hepato-biliary
Cohort 2 10 251
Nested case-control 1 814
Case-control 2 2491
Overall 5 13 556
Pancreas
Cohort 7 7759
Nested case-control 1 1141
Case-control 7 3293
Overall 15 12 193
a P value for heterogeneity within strata.
b P value for heterogeneity across strata.
560 https://doi.org/10.1016/j.annonc.2020.02.0120.94; P for heterogeneity across study design<0.001; Table 1
and Figure 1). For all pooled estimates, there was significant
between-study heterogeneity (P < 0.001). The RRs were
similar for colon (RR ¼ 0.77, 95% CI ¼ 0.71e0.84) and rectal
(RR ¼ 0.74, 95% CI ¼ 0.66e0.84) cancer (P for
heterogeneity ¼0.61; data not shown). The funnel plot
pointed out some publication bias, confirmed by the Egger’s
test (P ¼ 0.002), but not the Begg’s test (P ¼ 0.358;
supplementary Figure S2, available at Annals of Oncology on-
line). Publication bias was found in case-control studies
(Egger’s test P¼ 0.06), but not in cohort or nested case-control
ones (data not shown). Risk estimates were consistent across
strata of all covariates considered, except for year of publica-
tion (RR ¼ 0.59 before 2000, 0.77 in 2000e2009, and 0.75 in
2010e2018; P for heterogeneity ¼0.038; supplementary
Table S15, available at Annals of Oncology online).
Eleven studies provided estimates of the colorectal
cancer risk in relation to dose of aspirin (Figure 2). Overall,
they indicated that there was a linear dose-risk relation,
the RR being 0.90 (95% CI ¼ 0.85e0.96) for 75 mg/day,
0.89 (95% CI ¼ 0.84e0.95) for 81 mg/day, 0.87 (95% CI ¼
0.80e0.94) for 100 mg/day, 0.64 (95% CI ¼ 0.49e0.82) for
325 mg/day, and 0.50 (95% CI ¼ 0.34e0.74) for 500
mg/day.(CI) for regular aspirin use versus non-use by cancer site and study design
Pooled RR
(95% CI)
P valuea I2 (%) P valueb
0.77 (0.72e0.82) <0.001 62 <0.001
0.86 (0.78e0.94) <0.001 88
0.62 (0.56e0.69) <0.001 62
0.73 (0.69e0.78) <0.001 86
0.78 (0.62e0.98) e e 0.106
1.03 (0.90e1.18) 0.196 40
0.87 (0.58e1.31) <0.001 87
0.94 (0.76e1.16) <0.001 83
0.65 (0.54e0.80) 0.233 30 <0.001
0.90 (0.78e1.03) 0.641 0
0.54 (0.43e0.67) 0.970 0
0.67 (0.57e0.79) 0.006 57
0.88 (0.68e1.15) 0.575 0 0.015
0.56 (0.44e0.73) <0.001 78
0.61 (0.49e0.77) <0.001 76
0.58 (0.44e0.76) <0.001 84 <0.001
1.17 (0.98e1.40) e e
0.63 (0.48e0.83) <0.001 77
0.64 (0.51e0.82) <0.001 91
0.66 (0.47e0.94) <0.001 92 <0.001
1.11 (0.86e1.44) e e
0.34 (0.30e0.39) 0.450 0
0.62 (0.44e0.86) <0.001 95
0.79 (0.64e0.98) <0.001 90 0.103
0.95 (0.81e1.12) e e
0.73 (0.60e0.88) 0.110 64
0.78 (0.68e0.89) <0.001 84
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Figure 1. Forest plot of study-specific and pooled relative risk (RR) of colorectal cancer, and corresponding 95% confidence interval (CI), for regular aspirin use
versus non-use, overall and by study design.
CCFR, Colon Cancer Family Registry; DALS, Diet, Activity and Lifestyle Study; L, low dose aspirin; OFCCR, Ontario Familial Colorectal Cancer Registry; PLCO, Prostate,
Lung, Colorectal, and Ovarian cancer screening trial; PMH-CCFR, Postmenopausal Hormone StudyeColon Cancer Family Registry; R, regular dose aspirin.
C. Bosetti et al. Annals of OncologyTwenty-two studies provided estimates of the colorectal
cancer risk in relation to duration of aspirin use (Figure 3).
The RR declined up to 10 years of use (RR ¼ 0.96, 95% CI ¼
0.95e0.98, for 1 year, 0.89, 95% CI ¼ 0.85e0.93, for 3
years, 0.81, 95% CI ¼ 0.76e0.88, for 5 years, and 0.71, 95%
CI ¼ 0.63e0.80, for 10 years).Volume 31 - Issue 5 - 2020Head and neck cancer
Ten studies (one cohort study, two nested case-control studies,
and seven case-control studies) reported information on aspirin
use and the risk of head and neck cancer (oral, pharyngeal,
nasopharyngeal, and laryngeal cancer), including a total of 10
399 cases (Table 1 and supplementary Table S3, available athttps://doi.org/10.1016/j.annonc.2020.02.012 561
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Figure 2. Relative risk (RR) function describing the relation between dose
(mg/day) of aspirin use and colorectal cancer.
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Annals of Oncology C. Bosetti et al.Annals of Oncology online). Overall, there was no significant
association between regular aspirin use and the riskof head and
neck cancer (RR ¼ 0.94, 95% CI ¼ 0.76e1.16, P for heteroge-
neity<0.001). Only the cohort study reported a significant riskRe
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Figure 3. Relative risk (RR) function describing the relation between duration
(years) of aspirin use and colorectal cancer.
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562 https://doi.org/10.1016/j.annonc.2020.02.012reduction (RR¼ 0.78, 95%CI¼ 0.62e0.98), while no significant
association was observed in nested-case-control studies (RR ¼
1.03, 95% CI ¼ 0.90e1.18; P for heterogeneity ¼0.196) nor in
case-control ones (RR ¼ 0.87, 95% CI ¼ 0.58e1.31; P for het-
erogeneity <0.001; Table 1 and Figure 4). There was no evi-
dence of publication bias (Egger’s test P¼ 0.421; Begg’s test P¼
0.245; supplementary Figure S3, available atAnnals of Oncology
online). Risk estimates were consistent across strata of year of
publication and type of controls, but not of geographic area (P
for heterogeneity <0.001), largely due to one case-control
study conducted in China which reported a significant excess
risk (RR¼ 1.91, 95% CI¼ 1.52e2.41; supplementary Table S16,
available at Annals of Oncology online).
Squamous-cell esophageal cancer
Among 15 studies providing information on squamous-cell
esophageal cancer risk (supplementary Tables S4 and S10,
available at Annals of Oncology online), 13 studies, including
6211 cases, contributed to the risk estimate of regular aspirin
use versus non-use (Table 1). A significant reduced risk was
reported overall (RR ¼ 0.67, 95% CI ¼ 0.57e0.79). The RR
was 0.65 in four cohort studies, 0.54 (95% CI¼ 0.43e0.67) in
seven case-control studies, and 0.90 (95% CI¼ 0.78e1.03) in
two nested case-control studies (Table 1 and Figure 5). There
was a significant heterogeneity between studies (P¼ 0.006),
which was explained by study design (P for heterogeneity
<0.0001). No evidence of publication bias was detected
(Egger’s test P¼ 0.459; Begg’s test P¼ 0.272; supplementary
Figure S4, available at Annals of Oncology online). The risk
estimates were consistent across strata of all covariates
considered (i.e. geographic area, type of controls, end point,
and year of publication; supplementary Table S17, available
at Annals of Oncology online).
Supplementary Figure S5, available at Annals of Oncology
online, indicated a linear relation between duration of
aspirin use and squamous-cell esophageal cancer risk on the
basis of five studies providing information, with RRs of 0.88
(95% CI ¼ 0.77e0.99) for 5 years of use and 0.77 (95% CI ¼
0.60e0.99) for 10 years of use.
Esophageal and gastric cardia adenocarcinoma
Out of 12 studies providing information on aspirin use and
esophageal and gastric cardia adenocarcinoma (supplementary
Tables S5 and S11, available at Annals of Oncology online), 10
studies, including 3021 cases, contributed to quantify the risk
among regular aspirin use compared with non-use (Table 1). A
significant inverse relation was found overall (RR ¼ 0.61, 95%
CI¼ 0.49e0.77), and in eight case-control studies (RR¼ 0.56,
95% CI¼ 0.44e0.73), while the RR was 0.88 (95% CI¼ 0.68e
1.15) in two cohort studies (P for heterogeneity across study
design ¼0.015; Table 1 and Figure 6). There was significant
between-study heterogeneity overall and among case-control
studies (P < 0.001), but not among cohort studies. There was
no evidence of publication bias (Egger’s test P¼ 0.085; Begg’s
test P¼ 0.151; supplementary Figure S6, available at Annals of
Oncology online). The RRs were consistent across strata of all
covariates considered (i.e. geographic area, type of controls,Volume 31 - Issue 5 - 2020
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Figure 4. Forest plot of study-specific and pooled relative risk (RR) of head and neck cancer, and corresponding 95% confidence interval (CI), for regular aspirin use
versus non-use, overall and by study design.
C. Bosetti et al. Annals of Oncologyand year of publication; supplementary Table S18, available at
Annals of Oncology online).
There was a non-significant linear RR reduction with
increasing years of regular aspirin use, based on three studies
(RR ¼ 0.94, 95% CI ¼ 0.79e1.04, and 0.82, 95% CI ¼ 0.62e
1.09, for 5 and 10 years of use, respectively; supplementary
Figure S7, available at Annals of Oncology online).Figure 5. Forest plot of study-specific and pooled relative risk (RR) of squamous-cell
aspirin use versus non-use, overall and by study design.
Volume 31 - Issue 5 - 2020Stomach cancer
Sixteen studies reported information on aspirin use and
stomach cancer (supplementary Tables S6 and S12, avail-
able at Annals of Oncology online), of which 14 (six cohort
studies, one nested case-control, and seven case-control
studies) contributed to estimating the association foresophageal cancer, and corresponding 95% confidence interval (CI), for regular
https://doi.org/10.1016/j.annonc.2020.02.012 563
Figure 6. Forest plot of study-specific and pooled relative risk (RR) of adenocarcinoma of the esophagus and gastric cardia, and corresponding 95% confidence
interval (CI), for regular aspirin use versus non-use, overall and by study design.
EA, esophageal adenocarcinoma; GCA, gastric cardia adenocarcinoma.
Annals of Oncology C. Bosetti et al.regular aspirin use, including 9919 cases (Table 1). The RR
was 0.64 (95% CI ¼ 0.51e0.82) overall, 0.58 in six cohorts,
and 0.63 (95% CI ¼ 0.48e0.83) in seven case-control
studies, while one nested case-control study reported anFigure 7. Forest plot of study-specific and pooled relative risk (RR) of stomach ca
versus non-use, overall and by study design.
564 https://doi.org/10.1016/j.annonc.2020.02.012RR of 1.17 (95% CI ¼ 0.98e1.40; P of heterogeneity across
study design <0.001; Table 1 and Figure 7). Significant
between-studies heterogeneity was found overall and
among case-control or cohort studies (P < 0.001). Therencer, and corresponding 95% confidence interval (CI), for regular aspirin use
Volume 31 - Issue 5 - 2020
C. Bosetti et al. Annals of Oncologywas no evidence of publication bias (Egger’s test P ¼ 0.268;
Begg’s test P ¼ 0.784; supplementary Figure S8, available at
Annals of Oncology online). The RRs were consistent across
strata of all covariates considered, except geographic area
(RR ¼ 0.58, 95% CI ¼ 0.48e0.71, in the USA, 0.89, 95%
CI ¼ 0.65e1.23, in Europe, and 0.49, 95% CI ¼ 0.34e0.72,
in other areas; P for heterogeneity ¼0.034; supplementary
Table S19, available at Annals of Oncology online).
Eight studies indicated that the risk of stomach cancer
linearly decreased with increasing years of regular aspirin
use (RR ¼ 0.81, 95% CI ¼ 0.71e0.92, for 5 and 0.65, 95%
CI ¼ 0.50e0.85, for 10 years of use; supplementary
Figure S9, available at Annals of Oncology online).Hepato-biliary cancer
Eight studies provided information on aspirin use and risk of
hepato-biliary cancer (including hepatocellular carcinoma
and cholangiocarcinoma; supplementary Tables S7 and S13,
available at Annals of Oncology online) of which five studies
contributed to the estimate of regular aspirin use compared
with non-use (Table 1). The RR was 0.62 (95% CI ¼ 0.44e
0.86) overall (P for heterogeneity <0.001), 0.66 (95% CI ¼
0.47e0.94) in two cohort studies (P for heterogeneity
<0.001), 0.34 (95% CI ¼ 0.30e0.39) in two case-control
studies, and 1.11 in a nested case-control one (P for het-
erogeneity across study design <0.001; Table 1 and
Figure 8). The RRs were 0.71 (95% CI ¼ 0.46e1.09) for liver
cancer and 0.53 (95% CI ¼ 0.24e1.14) for chol-
angiocarcinoma (P for heterogeneity ¼0.51; data not
shown).
No evidence of publication bias was observed (Egger’s
test P ¼ 0.540; Begg’s test P ¼ 0.624; supplementary
Figure S10, available at Annals of Oncology online). After
stratifying studies for geographic area, risk estimates wereFigure 8. Forest plot of study-specific and pooled relative risk (RR) of hepato-biliary
versus non-use, overall and by study design.
HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma.
Volume 31 - Issue 5 - 2020not consistent across strata (RR ¼ 0.34, 95% CI ¼ 0.30e
0.39, in the USA, 0.75, 95% CI ¼ 0.31e1.81, in Europe, and
0.49, 95% CI ¼ 0.45e0.53, in other areas; P for heteroge-
neity <0.001; supplementary Table S20, available at Annals
of Oncology online).
Supplementary Figure S11, available at Annals of
Oncology online, shows a linear duration-risk relation,
although the 95% CI are extremely wide, since it was based
on three studies only.Pancreatic cancer
Twenty original publications reported risk estimates for
pancreatic cancer (supplementary Tables S8 and S14,
available at Annals of Oncology online). Fifteen studies
(seven cohort studies, one nested case-control study, and
seven case-control studies) were considered in the estimate
of regular aspirin use, including a total of 12 193 cases
(Table 1). An inverse association was found overall (RR ¼
0.78, 95% CI ¼ 0.68e0.89), in cohort (RR ¼ 0.79, 95% CI ¼
0.64e0.98, P for heterogeneity <0.001), in case-control
studies (RR ¼ 0.73), but not in one nested case-control
study (RR ¼ 0.95, 95% CI ¼ 0.81e1.12; Table 1 and
Figure 9). There was no evidence of publication bias (Egger’s
test P ¼ 0.136; Begg’s test P ¼ 0.216; supplementary
Figure S12, available at Annals of Oncology online). The
RRs were consistent across strata of all covariates (i.e.
geographic area, type of controls, and year of publication;
supplementary Table S13, available at Annals of Oncology
online).
Supplementary Figure S5, available at Annals of Oncology
online, shows linear dose-response relations between
duration of regular aspirin use and the risk of pancreatic
cancer, based on seven studies. The RRs for 5 and 10 yearscancer, and corresponding 95% confidence interval (CI), for regular aspirin use
https://doi.org/10.1016/j.annonc.2020.02.012 565
Figure 9. Forest plot of study-specific and pooled relative risk (RR) of pancreatic cancer, and corresponding 95% confidence interval (CI), for regular aspirin use
versus non-use, overall and by study design.
Annals of Oncology C. Bosetti et al.of regular aspirin use were 0.75 (95% CI ¼ 0.59e0.94) and
0.56 (95% CI ¼ 0.35e0.89), respectively.
DISCUSSION
The present comprehensive meta-analysis on aspirin and
colorectal and other digestive tract cancers confirms and
further quantifies the inverse association between aspirin
use and the risk of cancer of the colorectum, esophagus,
and stomach, and provides evidence of a protective effect
on hepato-biliary and pancreas cancer risk, as well. The
associations are consistent across sex, geographical areas,
and other covariates. For all neoplasms, the favorable effect
of aspirin tends to increase with longer duration of use, and
for colorectal cancer, with increasing dose.
Data on over 150 000 colorectal cancer cases provide
evidence of an about 30% reduced risk for regular aspirin
use as compared with non-use. A significant risk reduction
is reported for all study designs. There is, however, some
heterogeneity between studies, although almost all studies
provided RR estimates significantly below unity; moreover,
there is some evidence of publication bias, with various
small studies reporting stronger inverse associations. These
results confirm those of previous meta-analyses of obser-
vational studies6,8 and are consistent with the evidence
provided by a pooled analysis of RCTs of aspirin for the
prevention of cardiovascular diseases.3,20,21
Low dose aspirin (between 75 and 100 mg/day) conveys
a reduction of risk by 10%, regular-dose aspirin (325 mg/
day) by 35%, and high-dose aspirin (500 mg/day) by 50%.
This latter estimate should be cautiously interpreted, since566 https://doi.org/10.1016/j.annonc.2020.02.012it is based on a limited number of studies. A previous meta-
analysis of cohort studies reported an inverse relation be-
tween colorectal incidence, with significant and dose- and
frequency-risk relations.6 In a post-trial follow up of the
randomized Physicians’ Health Study, use of 325 mg of
aspirin every other day was not associated with a significant
reduction of colorectal cancer incidence.22 Similarly, in the
randomized Women’s Health Study alternate day use of low
dose aspirin (100 mg) for an average treatment of 10 years
did not lower colorectal cancer incidence,23 although in the
post-trial follow-up colorectal cancer risk was significantly
reduced.24 A pooled analysis of two RCTs of high-dose
aspirin use indicated that regular use of at least 300 mg/
day is effective in the primary prevention of colorectal
cancer.25 Moreover, an RCT of aspirin in the prevention of
colorectal cancer in carriers of the Lynch syndrome indi-
cated that 600 mg of aspirin per day significantly reduced
colorectal cancer incidence after a 3-year follow-up.26
With regard to the duration of aspirin use and colorectal
cancer risk, the risk reduction is by 20% for 5 years of use
and by 30% for 10 years of use. The risk levels off for longer
duration of use, although this result is difficult to interpret
as there are few studies that analyzed long-term aspirin use.
The meta-analysis of cohort studies by Ye et al.6 also sug-
gested that long-term (at least 5 years) use of aspirin is
required in order to show a protective effect on colorectal
cancer risk. In the pooled analysis of RCTs of aspirin use for
the prevention of cardiovascular diseases, the reduction in
colorectal cancer incidence and mortality was evident for
treatments of more than 5 years.20,21,27,28Volume 31 - Issue 5 - 2020
C. Bosetti et al. Annals of OncologyAspirin use is associated with about a 35%e40% risk
reduction of cancers of the esophagus and stomach, con-
firming the findings of previous meta-analyses.7,8 For
squamous-cell and stomach cancers, consistent results are
found in case-control and cohort studies, but the evidence
is less clear in nested case-control studies, while for
adenocarcinoma of the esophagus and gastric cancer, the
only two cohort studies do not show a significant associa-
tion. Since aspirin may cause gastrointestinal bleeding,29 it
is possible that at least part of the inverse association
observed is due to the avoidance of aspirin use in patients
with early symptoms of esophageal or stomach cancer. Data
from a few studies suggest linear duration-risk relations
between the use of aspirin and the risk of squamous-cell
esophageal and stomach cancer. The duration-risk relation
for adenocarcinoma of the esophagus and gastric cardia is
less clear. In the pooled analysis of RCTs, treatment with
aspirin for at least 5 years conveyed a significant protection
on esophageal cancer death after a latent period of 5 years,
while a non-significant reduction was observed for stomach
cancer mortality even after a long latency.21
With regard to cancers of the hepato-biliary tract (mainly
hepatocellular carcinoma), this meta-analysis provides some
evidence of a possible favorable effect of aspirin, as re-
ported in a previous meta-analysis.8 Data for the duration of
aspirin use are too limited to provide a meaningful
duration-risk relation. A recent study also reported that
aspirin is associated with a reduced risk of hepatocellular
cancer in patients with hepatitis B infection,30 although
further studies should confirm these associations.
While in a previous meta-analysis2 there was no evidence
of a significant pancreatic cancer risk reduction with aspirin
use, about a 20% significant reduction is observed in the
present meta-analysis as in a previous one,8 with a similar
risk reduction in case-control and cohort studies. Moreover,
an inverse duration-risk relation is found, with an RR of 0.56
for 10 years of regular aspirin use. The evidence accumu-
lated over the last few years therefore points to a favorable
effect of aspirin also on pancreatic cancer risk. In the pooled
analysis of RCTs, treatment with aspirin for at least 5 years
conveyed a significant protection on pancreatic cancer
death after a latent period of 5 years.21
Overall evidence does not support an association of
aspirin use with cancers of the head and neck.8 However,
this class includes different cancers, with variable charac-
teristics and etiological factors. Additional studies are
necessary to further assess the role of aspirin on each of
those neoplasms.
Among the possible limitations of our study, there are
inherent biases of observational studies. The inverse asso-
ciations observed in the present meta-analysis are generally
stronger in case-control than cohort studies. Although
cohort studies are less prone to recall or selection bias than
case-control studies, they generally collect data only at
baseline and lack information on exposure changes over
time, thus causing possible misclassification of aspirin
exposure. In any case, potential recall bias in case-control
studiesddue to possible more careful reporting of aspirinVolume 31 - Issue 5 - 2020use in cases than controlsdshould, if any, bias risk esti-
mates towards the null. Confounding by indicationddue to
selective avoiding of aspirin use in patients with early
symptoms of digestive tract cancersdmay partly explain
the stronger inverse associations observed in case-control
than cohort studies. The lower inverse associations re-
ported in nested case-control studies (often based on pre-
scription databases) can be explained by misclassification of
aspirin exposure in those studies, due to possible less
precise assessment of the actual aspirin use and lack of
information on over-the-counter use. For many of the
pooled estimates, there is a between-study heterogeneity,
which does not seem to be explained by the covariates
considered. Different study populations, baseline cancer
risks, prevalence of aspirin use, aspirin dose, inclusion of
patients for primary and secondary cardiovascular disease
prevention, and high variability in the definition of ‘regular’
use may be responsible of such heterogeneity. Finally, most
studies included in our meta-analysis did not have data on
other medications for cardiovascular prevention (such as
statins), which may confound the association between
aspirin and cancer risk.
From a biological point of view, the chemopreventive
effect of aspirin has been attributed to the inhibition of
cyclooxygenase (COX), the enzyme responsible for the
synthesis of prostaglandins. COX-2 isoform is abnormally
expressed in many cancer cell lines and is implicated in the
process of carcinogenesis, tumor growth, apoptosis, and
angiogenesis.1,31e34 Additional mechanisms include the in-
duction of apoptosis through COX-independent pathways,
such as the inhibition of nuclear factor-kappa b, the PIK3CA
pathway, and the up-regulation of tumor suppression
genes.33,34
In conclusion, the present meta-analysis provides further
evidence and quantification of a favourable effect of aspirin
on colorectal and other digestive tract neoplasms. It also
suggests that the protection tends to increase with longer
duration of use, and for colorectal, with increasing dose.
These results should be confirmed by the on-going primary
prevention trials.35e37
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